Chemistry: analytical and immunological testing – Peptide – protein or amino acid
Reexamination Certificate
2011-08-02
2011-08-02
Woodward, Cherie M (Department: 1647)
Chemistry: analytical and immunological testing
Peptide, protein or amino acid
C435S007100, C424S085200
Reexamination Certificate
active
07989210
ABSTRACT:
Methods for evaluating the likelihood that a subject will benefit from treatment with an agent for reducing the risk of a cardiovascular condition, by evaluating levels of Interleukin 1 Receptor-Like 1 (IL1RL-1) polypeptides in a sample comprising serum from the subject.
REFERENCES:
patent: 5217899 (1993-06-01), Shapiro et al.
patent: 5348879 (1994-09-01), Shapiro et al.
patent: 5786163 (1998-07-01), Hall
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6288218 (2001-09-01), Levinson
patent: 6323334 (2001-11-01), Kingsbury et al.
patent: 7087396 (2006-08-01), Tominaga et al.
patent: 7432060 (2008-10-01), Lee
patent: 2002/0072674 (2002-06-01), Criton et al.
patent: 2003/0124624 (2003-07-01), Tominaga et al.
patent: 2004/0048286 (2004-03-01), Lee
patent: 2005/0130136 (2005-06-01), Lee
patent: 2005/0203046 (2005-09-01), Schmitz et al.
patent: 2007/0042978 (2007-02-01), Girard et al.
patent: 2008/0003199 (2008-01-01), Lee
patent: 2009/0192078 (2009-07-01), Lee
patent: 6178687 (1994-06-01), None
patent: 7031479 (1995-02-01), None
patent: 98-07754 (1998-02-01), None
patent: 98-38311 (1998-09-01), None
patent: 99-34217 (1999-07-01), None
patent: 00-35951 (2000-06-01), None
patent: 00-35473 (2000-11-01), None
patent: 00-73498 (2000-12-01), None
patent: 01-70817 (2001-09-01), None
patent: 02-38794 (2002-05-01), None
patent: 03/094856 (2003-11-01), None
patent: 2004/056868 (2004-07-01), None
patent: 2007/127749 (2007-11-01), None
Albert et al., Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. Jun. 4, 2002;105(22):2595-9. Auer et al, “C-reactive protein and coronary artery disease,” Jpn Heart J., 43(6):607-619 (2002).
Aukrust et al., “Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy,” Am J Cardiol., 83(3):376-382 (1999).
Baumgarten et al., “Cytokines as emerging targets in the treatment of heart failure,” Trends Cardiovasc Med., 10(5):216-223 (2000).
Belch et al., “Oxygen free radicals and congestive heart failure,” Br Heart J., 65(5):245-248 (1991).
Blum et al., “Pathophysiological role of cytokines in congestive heart failure,” Annu. Rev. Med., 52:15-27 (2001) (abstract).
Brown, “Techniques for Mechanical Stimulation of cells in vitro: a review,” Journal of Biomechanics, 33:3-14 (2000).
Carter et al., “Regulation of ST2L expression of T helper (Th) type 2 cells,” Eur. J. Immunol., 31(10):2979-2985 (2001). (Abstract Only).
Chan et al., “Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes,” J Immunol., 167(3):1238-1244 (2001). (abstract).
Cheng et al., Mechanical strain tightly controls fibroblast growth factor-2 release from cultured human vascular smooth muscle cells. Circ Res. Jan. 1997;80(1):28-36. (Abstract).
Coyle et al., “Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses,” J Exp Med., 190(7):895-902 (1999).
De Keulenaer et al., “Identification of IEX-1 as a biomechanically controlled nuclear factor-kappaB target gene that inhibits cardiomyocyte hypertrophy,” Circ Res., 90(6):690-696 (2002).
Feldman et al., “C-reactive protein is an independent predictor of mortality in women with HIV-1 infection,” J. Acquir. Immune Defic. Syndr., 32(2):210-214 (2003). (abstract).
Feng et al., “Transcriptional profile of mechanically induced genes in human vascular smooth muscle cells,” Circ Res., 85(12):1118-23 (1999).
Forssmann et al., “The heart is the center of a new endocrine, paracrine, and neuroendocrine system,” Arch. Histol. Cytol., 52 Supp1:293-315 (1989). (Abstract).
Frangogiannis et al., “Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion,” Circulation., 98(7):699-710 (1998).
Galvani et al., “Prognostic influence of elevated values of cardiac troponin 1 in patients with unstable angina,” Circulation, 95(8):2053-2059 (1997). (Abstract).
GenBank Acc. No. NM—003856 (PRI Nov. 18, 2007).
GenBank Acc. No. NM—016232 (PRI Nov. 18, 2007).
GenBank Acc. No. NP—003847 (PRI Nov. 18, 2007).
GenBank Acc. No. NP—057316 (PRI Nov. 18, 2007).
GenBank Submission; NIH-1/NCBI; Accession No. AB022176 (PRI Sep. 15, 2007).
GenBank Submission; NIH/NCBI; Accession No. AB024518 (PRI Mar. 10, 1999).
GenBank Submission; NIH/NCBI; Accession No. AL117622 (printed Sep. 25, 2007) (2 pages).
GenBank Submission; NIH/NCBI; Accession No. D12763 (PRI Jan. 23, 2003).
GenBank Submission; NIH/NCBI; Accession No. E07714 (PAT Nov. 4, 2005).
GenBank Submission; NIH/NCBI; Accession No. E07716 (PAT Nov. 4, 2005).
GenBank Submission; NIH/NCBI; Accession No. E08652 (PAT Nov. 4, 2005).
GenBank Submission; NIH/NCBI; Accession No. U04317 (printed Aug. 23, 2000) (2 pages).
GenBank Submission; NIH/NCBI; Accession No. U04319 (printed Aug. 23, 2000) (2 pages).
GenBank Submission; NIH/NCBI; Accession No. X60184 (printed Sep. 25, 2007) (5 pages).
Goldstein, Am J Cardiol, Dec. 1981; 48(6):1147-54. (Abstract Only).
Gutstein et al., Role of inositol 1,4,5-trisphosphate receptors in regulating apoptotic signaling and heart failure. Heart Vessels. 1997;Suppl 12:53-7.
Gwechenberger et al., Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. Feb. 2, 1999;99(4):546-51.
Hanyu T, et al. Urinary Thrombomodulin in Patients with Rheumatoid Arthritis: Relationship to Disease Subset. 1999; 18:385-9.
Heeschen et al., Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. Capture Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment trial. J Am Coll Cardiol. May 2000;35(6):1535-42. Abstract Only.
Hirota et al., Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. Apr. 16, 1999;97(2):189-98.
Information Hyperlinked Over Proteins —Symbol IL1RL1.
Iwahana et al., Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem. Sep. 1999;264(2):397-406.
Izakov et al., Cooperative effects due to calcium binding by troponin and their consequences for contraction and relaxation of cardiac muscle under various conditions of mechanical loading. Circ Res. Nov. 1991;69(5):1171-84.
Januzzi et al., “Utility of amino-terminal pro-brain natriuretic Peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department,” Arch. Intern. Med., 166(3):315-320 (2006).
Joyce et al., Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol. Nov. 1994;24(11):2699-705.
Kida et al., Pathophysiological role of natriuretic peptides. Rinsho Byori. Aug. 1989;37(8):875-82. Abstract Only.
Kumar et al., “ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1,” J. Biol. Chem., 270(46):27905-27913 (1995).
Kumar et al., Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun. Jun. 27, 1997;235(3):474-8.
Kuroiwa et al., “Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma,” 19(2):151-159 (2000).
Kuroiwa K, et al., Identification of Human ST2 Protein in the Sera of Patients with Autoimmune Diseases. Biochemical and Biophysical Research Communications 2001; 284:1104-8.
Laine et al., Effect of ryanodine
Fish & Richardson P.C.
The Brigham and Women's Hospital, Inc.
Woodward Cherie M
LandOfFree
IL1RL-1 as a cardiovascular disease marker and therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL1RL-1 as a cardiovascular disease marker and therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL1RL-1 as a cardiovascular disease marker and therapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2692159